[1. Pec J, Chromej I, Martinaskova K, Chribikova I, Danilla T, Adamicova K, Babal P, Fetisovova Z, Frlickova Z, Lidaj J, Masarovicova A, Minarikova E, Musak L, Osusky P, Pec M, Plank L, Vodicka P, Hegyi V. Chronicka loziskova psoriaza: komplexny pohlad na problematiku a biologicka liecba. 1. vydanie. Banská Bystrica: Dali; 2006.]Search in Google Scholar
[2. Pec J, Urbancek S, Martinaskova K, Simaljakova M, Osusky P, Adamicova K, Adamovicova K, Adamkov M, Babal P, Cerkalova I, Fetisovova Z, Holy B, Chribikova I, Chromy Stefan, Kubatka P, Mensikova J, Mitterova V, Nejdkova A, Pajerchin D, Pec J jr., Pec M, Rasochova E, Stracenska J, Vrtikova E, Zaujec L. Liecba psoriazy acitretinom. 1. vydanie. Bratislava: Univerzita Komenského; 2007.]Search in Google Scholar
[3. European Medicines Agency, “http://www.ema.europa.eu,” [Online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. [Accessed 28 november 2017].]Search in Google Scholar
[4. U.S. Food and drug administration, “www.fda.gov,” [Online]. Available: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580419.htm#biosimilar. [Accessed 29 november 2017].]Search in Google Scholar
[5. Crommelin D, de Vliger J, Weinstein V, Muhlebach S, Shah V, Schellekens H. Different Pharma ceutical Products Need Similar Terminology. AAPS J 2014; 16(1): 11-14.10.1208/s12248-013-9532-0388952524065599]Search in Google Scholar
[6. Biosimilar resource center, “www.biosimilarsresourcecenter.org,” [Online]. Available: https://www.-biosimilarsresourcecenter.org/faq/what-is-a-biobetter/. [Accessed 29 november 2017].]Search in Google Scholar
[7. Halim L, Brinks V, Jiskoot W, Romeijn S, Praditpornsilpa K, Assawamakin A, Schellekens H. How bio-questionable are the different recombinant human erythropoietin copy products in Thailand?. Pharm Res 2014; 31(5): 1210-1218.10.1007/s11095-013-1243-924258097]Search in Google Scholar
[8. Schenider C. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 2013; 72(3): 315 - 318.10.1136/annrheumdis-2012-20294123390018]Search in Google Scholar
[9. Goel N, Chance K. Biosimilars in rheumatology: understanding the rigor of their development. Rheumatology (Oxford) 2017; 56(2): 187-197.10.1093/rheumatology/kew206541092827241704]Search in Google Scholar
[10. Jahnsen J. Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients. Therap Adv Gastroenterol 2016; 9(3): 322-329.10.1177/1756283X16636764483010627134662]Search in Google Scholar
[11. Transparency Market Research, “www.prnewswire.com,” [Online]. Available: https://www.prnewswire.com/news-releases/global-biologics-market-will-be-worth-us479-752-million-by-2024-global-industry-analysis-size-share-growth-trends-and-forecast-2016---2024-tmr-596150181.html. [Accessed 30 november 2017].]Search in Google Scholar
[12. Reuters, “www.reuters.com,” [Online]. Available: https://www.reuters.com/article/us-health-pharmaceuticals-spending/global-prescription-drug-spend-seen-at-1-5-trillion-in-2021-reportidUSKBN13V0CB. [Accessed 30 november 2017].]Search in Google Scholar
[13. Genetic engineering and Biotechnology news, “www.genengnews.com,” [Online]. Available: https://www.genengnews.com/the-lists/the-top-15-best-selling-drugs-of-2016/77900868. [Accessed 30 november 2017].]Search in Google Scholar
[14. INESS, “www.cenastatu.sk,” [Online]. Available: http://www.cenastatu.sk/teachers/vvv_full_2016.pdf. [Accessed 29 november 2017].]Search in Google Scholar
[15. IMS health, “IMS data,” 2016.]Search in Google Scholar
[16. Forbes, “www.forbes.com,” [Online]. Available: https://www.forbes.com/sites/matthewherper/2013/08/11/the-cost-of-inventing-a-new-drug-98-companies-ranked/#7b5fb3042f08. [Accessed 30 november 2017].]Search in Google Scholar
[17. Pharmatimes online, “www.pharmatimes.com,” [Online]. Available: http://www.pharmatimes.com/news/over_700_biosimilars_now_in_development_worldwide_report_1002547. [Accessed 30 november 2017].]Search in Google Scholar
[18. RAPS - Regulatory affairs professionals society, “www.raps.org,” [Online]. Available: http://www.raps.org/Regulatory-Focus/News/2017/03/31/27240/Are-Biosimilars-Interchangeable-in-the-EU-A-New-Perspective/. [Accessed 1 december 2017].]Search in Google Scholar
[19. Baker M, Reynolds H, Lumicisi B, Bryson C. Immunogenicity of protein therapeutics. Self Nonself 2010; 1(4): 314-322.10.4161/self.1.4.13904306238621487506]Search in Google Scholar
[20. Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J, Lakatos P, Mantzaris P, van der Woude J, Panes J, Peyrin-Biroulet L. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. J Crohns Colitis 2017; 11(1): 26-34.10.1093/ecco-jcc/jjw19827927718]Search in Google Scholar
[21. Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M, Popovian R, Uy J. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Adv Ther 2017; 33(12): 2160-2172.10.1007/s12325-016-0431-5512618727798772]Search in Google Scholar
[22. Alten R, Cronstein B. Clinical trial development for biosimilars. Semin Arthritis Rheum 2015; 44(6): Suppl S2-8.10.1016/j.semarthrit.2015.04.00226058550]Search in Google Scholar
[23. Hallersten A, Furst W, Mezzasalma R. Physicians prefer greater detail in the biosimilar label (SmPC) - Results of a survey across seven European countries. Regul Toxicol Pharmacol 2016; 77: 275-281.10.1016/j.yrtph.2016.03.02127041395]Search in Google Scholar
[24. Peyrin-Biroulet L, Lonnfors S, Roblin X, Avedano L. Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations. J Crohns Colitis 2017; 11(1): 128-133.10.1093/ecco-jcc/jjw138]Search in Google Scholar
[25. Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis 2014; 8(11): 1548-1550.10.1016/j.crohns.2014.06.007]Search in Google Scholar
[26. Danese S, Fiorino G, Michetti P. Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey. J Crohns Colitis 2016; 10(11): 1362-1365.10.1093/ecco-jcc/jjw090]Search in Google Scholar
[27. Rovensky J, Jurgos L, Pec J. 58. list racionálnej farmakoterapie - Racionálna liečba biologicky podobnými liekmi v indikáciách bioterapeutík. Štandarný diagnostický a terapeutický postup 2013; 16(7): 1-4.]Search in Google Scholar
[28. Generics and Biosimilars initiative, “http://www.gabionline.net/,” [Online]. Available: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe. [Accessed 29 november 2017].]Search in Google Scholar
[29. U.S. Food and drug administration, “www.fda.gov,” [Online]. Available: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM560162.pdf. [Accessed 1 december 2017].]Search in Google Scholar
[30. U.S. Food and drug administration, “www.fda.gov,” [Online]. Available: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587378.htm. [Accessed 1 december 2017].]Search in Google Scholar
[31. Khraishi M, Stead D, Lukas M, Scotte F, Schmid H. Biosimilars: A Multidisciplinary Perspective. Clin Ther 2016; 38(5): 1238-1249.10.1016/j.clinthera.2016.02.023]Search in Google Scholar
[32. European Medicine Agency, “www.ema.europa.eu,” [Online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf. [Accessed 2 december 2017].]Search in Google Scholar
[33. European Medicine Agency, “www.ema.europa.eu,” [Online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf. [Accessed 2 december 2017].]Search in Google Scholar
[34. Jorgensen K, Olsen I, Lorentzen M, Bolstad N, Haavardsholm E, Lundin K, Mork C, Jahnsen J, Kvien T, NOR-SWITCH study group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017; 389(10086): 2304-2316.10.1016/S0140-6736(17)30068-5]Search in Google Scholar
[35. Healio Gastroenterology, “www.healio.com,” [Online]. Available: https://www.healio.com/gastroenterology/inflammatory-bowel-disease/news/online/%7B10599c7d-b5ee-4646-b4c1-59dc1a0b918b%7D/nor-switch-switching-to-remicade-biosimilar-safe-noninferior. [Accessed 3 december 2017].]Search in Google Scholar
[36. Kay J, Schoels M, Dorner T, Emery P, Kvien T, Smolen J, Breedveld F, Biosimilars to treat rheu diseases task force. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis 2017, no. pii: annrheumdis-2017-211937. doi: 10.1136/annrheumdis-2017-211937. [Epub ahead of print].10.1136/annrheumdis-2017-21193728866648]Search in Google Scholar
[37. PubMed Health, “www.ncbi.nlm.nih.gov,” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0095881/. [Accessed 3 december 2017].]Search in Google Scholar
[38. Fleischmann R. Therapy: Biosimilars in rheumatology - why, how and when in 2017. Nat Rev Rheumatol 2017; 13(12): 701-703.10.1038/nrrheum.2017.17929097811]Search in Google Scholar
[39. Moots R, Azevedo V, Coindreau J, Dorner T, Mahqoub E, Mysler E, Scheinberg M, Marshall L. Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. Curr Rheumatol Rep 2017; 19(37): 1-16.10.1007/s11926-017-0658-4548659528623625]Search in Google Scholar
[40. Glintborg B, Sorensen I, Loft A, Lindegaard H, Linauskas A, Hendricks O, Hansen I, Jensen D, Manilo N, Espesen J, Klarlund M, Grydehoj J, Dieperink S, Kristensen S, Olsen J, Nordin H, Chrysidis S, Dalsgaard Pedersen D, Sorensen M, Andersen L, Gron K, Krogh N, Pedersen L, Hetland M. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 2017; 76(8): 1426-1431.10.1136/annrheumdis-2016-21074228473425]Search in Google Scholar
[41. Glintborg B, Sorensen I, Loft A, Heltand M. FRI0190 Clinical outcomes from a nationwide nonmedical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. Results from the danbio registry. in Conference Paper: Annual European Congress of Rheumatology, 2017.10.1136/annrheumdis-2017-eular.1703]Search in Google Scholar
[42. Kim W, Buske C, Oqura M, Jurczak W, Sancho J, Zhavrid E, Kim J, Hernandez-Rivas J, Prokharau A, Vasilica M, Nagarkar R, Osmanov D, Kwak L, Lee S, Lee S, Bae Y, Coiffier B. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol 2017; 4(8): e362-e373. doi: 10.1016/S2352-3026(17)30120-5. Epub 2017 Jul 14.]Search in Google Scholar
[43. Jurczak W, Moreira I, Kanakasetty G, Munhoz E, Echeveste M, Giri P, Castro N, Pereira J, Akria L, Alexeev S, Osmanov E, Zhu P, Alexandrova S, Zubel A, Harlin O, Amersdorffer J. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol 2017; 4(8): e350-e361. doi: 10.1016/S2352-3026(17)30106-0. Epub 2017 Jul 14.]Search in Google Scholar
[44. Missouri State Tumor Registrars Association - MOSTRA, “https://mostra-ctr.org,” [Online]. Available: https://mostra-ctr.org/AboutUs/RegistrarsandOurCode/TheOriginoftheCancerRegistry/tabid/145/Default.aspx.[Accessed 3 december 2017].]Search in Google Scholar
[45. Ondrusova M. Narodny onkologicky register Slovenskej republiky - zakladny zdroj informacii v zdravotnickej politike. Onkologia (Bratisl.) 2006; 1: 64-65.]Search in Google Scholar
[46. NCZI - Narodne centrum zdravotnickych informacii, “http://www.nczisk.sk,” [Online]. Available: http://www.nczisk.sk/Publikacie/Pages/Edicia-analytickych-publikacii.aspx. [Accessed 3 december 2017].]Search in Google Scholar
[47. Pec J, Martinaskova K, Valentova V, Vorcakova K, Adamicova K, Urbancek S, Lipovsky P, Baloghova J, Drotarova K, Fetisovova Z, Hemza M, Chribikova I, Jautova J, Lidaj J, Linkeschova E, Masarovicova A, Osusky P, Palotai T, Pec M, Pecova K, Polak I, Psotova M, Surnakova K, Salkovska J, Svec J, Simaljakova M, Tindirova M, Vojtas I, Zaujec L. Systemova liecba psoriazy u dospelych. 1. vydanie. Bratislava: Univerzita Komenskeho; 2010.]Search in Google Scholar
[48. Gliklich R, Dreyer N. Registries for evaluating outcomes: User´s guide. 2 ed. Rockville, MD; Agency for Healthcare Research and quality; 2010.]Search in Google Scholar
[49. Sokka T, Krishnan E, Hakkinen A, Hannonen P. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum 2003; 48(1): 59-63.10.1002/art.1073112528104]Search in Google Scholar
[50. Kvien T, Uhlig T. The Oslo experience with arthritis registries. Clin Exp Rheumatol 2003; 21(5 Suppl 31): S118-122.]Search in Google Scholar
[51. Silman A, Klareskog L, Breedveld F, Bresnihan B, Maini R, Van Riel P, Symmons D. Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for Biological Compounds. Ann Rheum Dis 2000; 59(6): 419-420.10.1136/ard.59.6.419175317010834856]Search in Google Scholar
[52. Mariette X, Gottenberg J, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011; 50(1): 222-229.10.1093/rheumatology/keq36821148156]Search in Google Scholar
[53. Hetland M, Unkerskov J, Ravn T, Friis M, Tarp U, Andersen L, Petri A, Khan H, Stenver D, Hansen A, Ostergaard M. Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO). Scand J Rheumatol 2005; 34(1): 40-44.10.1080/0300974051001796815903024]Search in Google Scholar
[54. Elkayam O, Pavelka K. Biologic registries in rheumatology: lessons learned and expectations for the future. Autoimmun Rev 2012; 12(2): 329-33610.1016/j.autrev.2012.05.00922683382]Search in Google Scholar
[55. Alrubairy L, Rikaby I, Hutchings H, Williams J. Can the inflammatory bowel disease biologics registry lead to improved quality of care?. Journal of Taibah University Medical Sciences 2015; 10(3): 373-375.10.1016/j.jtumed.2015.02.008]Search in Google Scholar
[56. Markman M. Maurie Markman on the Groundbreaking TAPUR Trial. Oncology (Williston Park) 2017; 31(3): 158-168.]Search in Google Scholar
[57. Gladman D, Ritchlin C, Helliwell P. Psoriatic arthritis clinical registries and genomics. Ann Rheum Dis 2005; 64(Suppl 2): 103-105.10.1136/ard.2004.030973176685815708920]Search in Google Scholar
[58. European Medicines Agency, “http://www.ema.europa.eu,” [Online]. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000037.jsp&mid=WC0b01ac0580023e7a. [Accessed 3 december 2017].]Search in Google Scholar
[59. Elder J. Psoriasis clinical registries, genetics, and genomics. Ann Rheum Dis 2017; 64(Suppl 2): 106-107.10.1136/ard.2004.030833176687015708921]Search in Google Scholar
[60. Struve C. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation. Yale J Health Policy Law Ethics 2005; 5(2): 587-669.]Search in Google Scholar
[61. Garattini S, Bertele V. How can we regulate medicines better?. BMJ 2007; 335(7624): 803-805.10.1136/bmj.39281.615706.94203474317947785]Search in Google Scholar
[62. Zink A, Askling J, Dixon W, Klareskog L, Silman A, Symmons D. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009; 68(8): 1240-1246.10.1136/ard.2008.09192618647854]Search in Google Scholar
[63. Steliarova-Foucher E, Colombet M, Ries L, Moreno F, Doyla A, Bray F, Hesseling P, Shin H, Stiller C, IICC-3 contributors. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol 2017; 18(6): 719-731.10.1016/S1470-2045(17)30186-9]Search in Google Scholar
[64. Crocetti E, Buzzoni C. Do big numbers assure high-quality of data?. Lancet Haematol 2017; 4(7): e309. doi: 10.1016/S2352-3026(17)30107-2.10.1016/S2352-3026(17)30107-2]Search in Google Scholar
[65. Sutka R, Pec J, Pecova T. Centralised biological therapy registry for moderate to severe plaque psoriasis - overview and methodology. Acta Medica Martiniana 2016; 16(1): 36-48.10.1515/acm-2016-0005]Search in Google Scholar
[66. NCZI - Narodne centrum zdravotnickych informacii, “http://www.nczisk.sk,” [Online]. Available: http://www.nczisk.sk/Registre/Narodne-zdravotne-registre/Pages/default.aspx. [Accessed 3 december 2017].]Search in Google Scholar
[67. Pavelka K, Sedova L, Hejduk K, Dusek L. 15 years experience with biological therapy of inflammatory rheumatic diseases in Czech national register ATTRA. Cas Lek Cesk 2016; 155(6): 285-293.]Search in Google Scholar
[68. Kojanova M, Fialova J, Cetkovska P, Gkalpakiotis S, Jircikova J, Dolezal T, Arenberger P, Skupina Biorep. Analýza pacientů se středně těžkou až těžkou psoriázou před zahájením biologické léčby v České republice - údaje z registru BIOREP 2005-2016. Ces-slov Derm 2016; 91(5): 223-232.]Search in Google Scholar
[69. Czech National Cancer Registry (CNCR), “http://www.uzis.cz,” [Online]. Available: http://www.uzis.cz/en/registers/national-health-registers/czech-national-cancer-registry. [Accessed 3 december 2017].]Search in Google Scholar
[70. CREDIT-Cesky registr IBD pacientu na biologicke lecbe, “http://credit.registry.cz,” [Online]. Available: http://credit.registry.cz/index-en.php?pg=participating-centres. [Accessed 3 december 2017].]Search in Google Scholar
[71. Ministry of Health of Slovak Republic, “http://www.health.gov.sk,” [Online]. Available: http://www.health.gov.sk/?strategia-v-zdravotnictve. [Accessed 12 január 2018].]Search in Google Scholar